AstraZeneca Pays $200M Upfront For Global Rights To Targacept's MDD Candidate

With achievement of milestones, deal could yield $1.24 billion for Phase IIb antidepressant.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet